The "age" of understanding VKA dose

Blood

Volumn 116, Issue 26, 2010, Pages 5789-5790

  Goldenberg, Neil A ^a,b   Crowther, Mark A ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; CYTOCHROME P450; CYTOCHROME P450 2C9; MENADIONE EPOXIDE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN;

AGE; DRUG SAFETY; ENVIRONMENTAL FACTOR; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; NOTE; PRIORITY JOURNAL; PROTHROMBIN TIME;

EID: 78650642258     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-09-307900     Document Type: Note

References (4)

1. Nowak-Göttl U, Dietrich K, Schaffranek D, et al. In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. Blood. 2010;116(26):6101-6105.
2. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106(7):2329-2333.
3. Streif W, Andrew M, Marzinotto V, et al. Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients. Blood. 1999;94(9):3007-3014.
4. Takahashi H, Ishikawa S, Nomoto S, et al. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin Pharmacol Ther. 2000;68(5):541-55.